Back to discover
Drug
antineoplaston A10
In clinical developmentEmerging researchEarly-to-mid development
Also known as Antineoplaston A 10, BENZENEACETAMIDE, N-((3S)-2,6-DIOXO-3-PIPERIDINYL)-, BENZENEACETAMIDE, N-(2,6-DIOXO-3-PIPERIDINYL)-, (S)-.
1
Research papers
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Research2024-04-01Clinical cancer research : an official journal of the American Association for Cancer Research
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Phase II Study of Oral Antineoplastons A10 and AS2-1 in Women With Advanced Breast Cancer
Clinical trial2013-07-10Withdrawn · ClinicalTrials.gov
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
antineoplaston A10
Aliases & brands
Antineoplaston A 10BENZENEACETAMIDE, N-((3S)-2,6-DIOXO-3-PIPERIDINYL)-BENZENEACETAMIDE, N-(2,6-DIOXO-3-PIPERIDINYL)-, (S)-
RxNorm CUI
18062
ChEMBL ID
CHEMBL1980825
UNII
16VY3TM7ZO
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY7
registered trials across all phases
7
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 27
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Benzeneacetamides1Piperidones1Uterine Cervical Neoplasms1
Journals, researchers & institutions
Top journals
- Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers
- Cai H1
- Huang X1
- Li B1
- Li G1
- Liu F1
- Liu T1
- Liu W1
- Lou H1
Leading institutions
free-text, unnormalised
- Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)1
- Henan Cancer Hospital1
- Hunan Cancer Hospital1
- Sun Yat-sen University Cancer Center1
- Union Hospital1
- Zhongnan Hospital of Wuhan University1
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials